[go: up one dir, main page]

DE69738397D1 - Verfahren zur aufreinigung von apolipoprotein-a oder apolipoprotein-e aus menschlichem plasma - Google Patents

Verfahren zur aufreinigung von apolipoprotein-a oder apolipoprotein-e aus menschlichem plasma

Info

Publication number
DE69738397D1
DE69738397D1 DE69738397T DE69738397T DE69738397D1 DE 69738397 D1 DE69738397 D1 DE 69738397D1 DE 69738397 T DE69738397 T DE 69738397T DE 69738397 T DE69738397 T DE 69738397T DE 69738397 D1 DE69738397 D1 DE 69738397D1
Authority
DE
Germany
Prior art keywords
apolipoprotein
apoe
apoa
human plasma
atherosclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69738397T
Other languages
English (en)
Inventor
Stefan Winge
Sara Wiklund
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esperion Therapeutics Inc
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9603068A external-priority patent/SE9603068D0/xx
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Application granted granted Critical
Publication of DE69738397D1 publication Critical patent/DE69738397D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69738397T 1996-08-23 1997-08-22 Verfahren zur aufreinigung von apolipoprotein-a oder apolipoprotein-e aus menschlichem plasma Expired - Lifetime DE69738397D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9603068A SE9603068D0 (sv) 1996-08-23 1996-08-23 Process for purifying a protein
US2538796P 1996-09-04 1996-09-04
PCT/SE1997/001393 WO1998007751A1 (en) 1996-08-23 1997-08-22 A process for purifying apolipoprotein a or apolipoprotein e from human plasma

Publications (1)

Publication Number Publication Date
DE69738397D1 true DE69738397D1 (de) 2008-01-31

Family

ID=26662734

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69738397T Expired - Lifetime DE69738397D1 (de) 1996-08-23 1997-08-22 Verfahren zur aufreinigung von apolipoprotein-a oder apolipoprotein-e aus menschlichem plasma

Country Status (7)

Country Link
EP (1) EP0934337B1 (de)
JP (1) JP2001522349A (de)
AT (1) ATE381577T1 (de)
AU (1) AU731021B2 (de)
CA (1) CA2274241C (de)
DE (1) DE69738397D1 (de)
WO (1) WO1998007751A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306433B1 (en) 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US7205280B2 (en) * 1998-03-11 2007-04-17 Cognosci, Inc. Methods of suppressing microglial activation
DE19963420A1 (de) * 1999-12-28 2001-07-12 Sebo Gmbh Gewinnung von biologischen Komponenten aus Körperflüssigkeiten
CA2401755A1 (en) * 2000-03-03 2001-09-07 Smithkline Beecham Biologicals S.A. Vaccine for the treatment of artherosclerosis
CN103396479A (zh) 2007-08-17 2013-11-20 Csl百灵有限公司 α-1-抗胰蛋白酶和载脂蛋白A-I的纯化方法
US20110293557A1 (en) 2008-06-13 2011-12-01 Proyecto De Biomedicina Cima, S.L. Conjugates for the administration of biologically active compounds
CN102127165B (zh) * 2010-01-15 2013-09-04 上海莱士血液制品股份有限公司 一种从血浆组分四沉淀中制备高纯ApoA-I的生产工艺
CN110172093A (zh) 2013-06-05 2019-08-27 杰特有限公司 制备载脂蛋白a-i的方法
CN107033237B (zh) * 2017-05-11 2021-07-20 深圳市卫光生物制品股份有限公司 一种人血浆载脂蛋白a-i的分离纯化方法
CN110590937A (zh) * 2018-06-13 2019-12-20 杨宝田 一种人血载脂蛋白a1制品的制备方法及应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335077C (en) * 1988-02-08 1995-04-04 Henri Isliker Process for the manufacture of apolipoproteins from human blood plasma or serum

Also Published As

Publication number Publication date
CA2274241A1 (en) 1998-02-26
EP0934337A1 (de) 1999-08-11
CA2274241C (en) 2003-05-27
JP2001522349A (ja) 2001-11-13
WO1998007751A1 (en) 1998-02-26
EP0934337B1 (de) 2007-12-19
AU3876297A (en) 1998-03-06
ATE381577T1 (de) 2008-01-15
AU731021B2 (en) 2001-03-22

Similar Documents

Publication Publication Date Title
SE9603068D0 (sv) Process for purifying a protein
ATE226960T1 (de) Verfahren zur herstellung von cardiodilatin- fragmenten, hochgereinigte cardiodilatin- fragmente und zwischenprodukte zu deren herstellung
UA66745C2 (en) INTERLEUKIN-1b-CONVERTING ENZYME INHIBITORS, PHARMACEUTICAL COMPOSITION AND A METHOD FOR TREATMENT OF DISEASES
UA39135C2 (uk) Спосіб фракціонування розчину
DE69629949D1 (de) Aktivierte verbindungen und verfahren zur herstellung und reiningung
DE69508859D1 (de) Verfahren zur Reinigung von (-)-n-Isopulegol sowie gereinigtes (-)-n-Isopulegol enthaltende Zitrusparfümzusammensetzungen
ATE225368T1 (de) Verfahren zur reinigung von faktor viii
ATE200293T1 (de) Verfahren zur chromatographischen reinigung und trennung von nucleinsäuregemischen
EP0785785A4 (de) Verfahren zur bekämpfung von mit neuropeptiden zusammenhängenden erkrankungen
ZA99133B (en) Transgenic rabbit that expresses a functional human lipoprotein (A).
DK1003546T3 (da) Fremgangsmåde til behandling af patienter ramt af dissemineret sklerose ved anvendelse af konsensus interferon
DE69738397D1 (de) Verfahren zur aufreinigung von apolipoprotein-a oder apolipoprotein-e aus menschlichem plasma
ATE299889T1 (de) Neues verfahren zur trennung von proteinen unter verwendung eines ca++ enthaltenden elutionsmittels
ATE179717T1 (de) Verfahren zur reinigung von menschlichem albumin
ATE240743T1 (de) Verfahren und substanzen gegen protozoen
SE9603303D0 (sv) Process for purifying a protein
DE69502119D1 (de) Verfahren zur Herstellung von vorgespannten Kugelumlaufspindeln
DE69531308D1 (de) Verfahren zur Herstellung von gereinigten papillomavirus Proteinen
DE69024105D1 (de) Verfahren zur Herstellung von gereinigten Albuminlösungen
ATE509028T1 (de) Ionen-austausch-chromatographische trennung von glp-1 und verwandten peptiden
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
ATE222925T1 (de) Verbessertes verfahren zur herstellung von faktor viii
DE69820580D1 (de) Verfahren zur Abtrennung von Metallen durch micellare Ultrafiltration, geeignet zur Behandlung von radioaktiven Abfallstoffen
DE69515206D1 (de) Verfahren zur Herstellung von Glycidylacrylat oder Glycidylmethacrylat
DE69416103D1 (de) Verdrängungschromatographisches verfahren und gereinigtes hämoglobin

Legal Events

Date Code Title Description
8332 No legal effect for de